Interius BioTherapeutics presents preclinical data at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting demonstrating the safety and efficacy of its lead in vivo cell-specific gene medicine candidate, INT2104, for treating B-cell malignancies. INT2104 is a targeted lentiviral vector-based therapy that transduces T cells and NK cells upon intravenous administration, without requiring preconditioning chemotherapy. In vivo studies in humanized mice and cynomolgus macaques showed that a single intravenous administration of INT2104 resulted in sustained B cell depletion and antitumor activity. A GLP toxicology study established a favorable safety profile, providing support for clinical entry of INT2104 this year for B-cell malignancies.